Ozempic, a medication used to treat type 2 diabetes and promote weight loss, is gaining popularity in the pharmaceutical market. This is due to its effectiveness in managing blood sugar levels and its ability to support overall health and wellness. The increased use of Ozempic and other drugs in the GLP-1 drug class reflects a growing trend among consumers who prioritize their health.
As a result of this trend, various sectors within the US retail market are also being impacted. Companies such as Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, and Walmart are mentioned in this report as potential targets for the effects of widespread GLP-1 drug use on the retail industry.
Subscribers can access this exclusive report by logging in online. This document provides valuable insights into how GLP-1 drug use is affecting the retail industry and what businesses can do to adapt to these changes. If you are not currently a subscriber, you can learn more about subscriptions and gain access to relevant research on this topic.